Electrocore Inc (ECOR) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Electrocore Inc   (NASDAQ: ECOR)

Select the Financial Report: Select the Period:


Description of Electrocore Inc's Business Segments


Electrocore Inc. is a medical technology company primarily focused on developing non-invasive therapies to treat pain and neurological disorders. Here’s a detailed look at the segments, products, and services offered by Electrocore:

Segments

1. Neuromodulation:
- This segment represents Electrocores primary focus, utilizing neuromodulation techniques to alter nerve activity for therapeutic purposes. Neuromodulation has applications in chronic pain management and other neurological conditions.

2. Pain Management:
- Electrocore provides treatments aimed at alleviating various types of pain, including but not limited to migraine and cluster headaches. The treatments involve non-invasive devices that target specific nerves to help mitigate pain.

3. Chronic Conditions:
- The company also focuses on broader chronic health issues, looking to provide long-term solutions for managing conditions that can have a significant impact on patient quality of life.

Products

1. gammaCore®:
- This is Electrocores flagship product, a non-invasive handheld device designed for the acute treatment of cluster headaches and migraine. It works by delivering electrical stimulation through the skin over the cervical vagus nerve, aiming to disrupt pain transmission.
- Indications: gammaCore has received FDA clearance for the treatment of episodic and chronic cluster headaches as well as migraines.
- Versions: The gammaCore device comes in different versions, including gammaCore Sapphire, which features Bluetooth connectivity options for enhanced patient tracking and monitoring.

2. gammaCoreâ„¢ EV:
- A portable version of the gammaCore designed for at-home use. This device offers similar stimulation capabilities but is tailored for ease of use in a non-clinical setting, making it accessible for ongoing patient management.

3. gammaCoreâ„¢ Nerve Stimulation System:
- This system can be integrated into broader pain management protocols, offering physicians and patients a comprehensive tool for managing conditions like chronic migraines or headaches.

Services

1. Patient Support Programs:
- Electrocore offers various patient support programs aimed at guiding patients through their treatment journey with gammaCore devices. This includes education on device usage, management of treatment schedules, and follow-up support to encourage adherence to therapy.

2. Healthcare Professional Training:
- The company provides training and educational resources to healthcare providers to ensure they are knowledgeable about the devices proper usage and the underlying principles of neuromodulation. This support can enhance patient care and improve treatment outcomes.

3. Clinical Trials and Research Initiatives:
- Electrocore is involved in ongoing research to expand the indications for its products and to enhance understanding of their efficacy in various patient populations. They may collaborate with academic institutions and healthcare organizations to conduct clinical trials that provide data on the effectiveness and safety of their therapies.

4. Telehealth Capabilities:
- With the rise of telehealth, Electrocore may also offer digital solutions to monitor patient progress remotely, allowing healthcare providers to track outcomes, adjust treatment plans, and provide ongoing support through virtual visits.

5. Patient Education and Resources:
- The company emphasizes educating patients about their conditions and the benefits of using gammaCore. This may include informational materials, webinars, and interactive sessions designed to empower patients in managing their health.

In summary, Electrocore Inc. is dedicated to the development of non-invasive neuromodulation therapies focusing on the treatment of pain and neurological disorders, primarily through their flagship product, gammaCore. Their services and support systems are designed to enhance patient experience and engagement in their treatments.


Composition of Electrocore Inc Revenues by Segments

 
United States Rx    79.25 % of total Revenue
General Wellness    16.96 % of total Revenue
Outside The United States    5.36 % of total Revenue
T A C S T I M    0.45 % of total Revenue
In License Or Other    0.33 % of total Revenue
Product UNITED STATES    96.81 % of total Revenue
Product UNITED KINGDOM    4.98 % of total Revenue
Product Other Countries    0.38 % of total Revenue
License JAPAN    0.18 % of total Revenue
Bioelectronic Innovations Segment    102.35 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
United States Rx 7.42 79.25 %
General Wellness 1.59 16.96 %
Outside The United States 0.50 5.36 %
T A C S T I M 0.04 0.45 %
In License Or Other 0.03 0.33 %
Product UNITED STATES 9.07 96.81 %
Product UNITED KINGDOM 0.47 4.98 %
Product Other Countries 0.04 0.38 %
License JAPAN 0.02 0.18 %
Bioelectronic Innovations Segment 9.58 102.35 %
Total 9.36 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
United States Rx 48.27 % -
General Wellness 43.58 % -
Outside The United States - -
T A C S T I M -53.33 % -
In License Or Other 55 % -
Product UNITED STATES 46.07 % -
Product UNITED KINGDOM 3.33 % -
Product Other Countries -23.4 % -
License JAPAN 13.33 % -
Bioelectronic Innovations Segment 42.64 % -
Total 39.64 % -70.54 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Bioelectronic Innovations Segment 8.36 87.27 %
Total -5.27 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Bioelectronic Innovations Segment 46.58 % -
Total - -




Annual Report on Electrocore Inc Divisions, Sales by Country

 
United States Rx   United States Rx Segment contribution to total sales 75.73 % of total Revenue
General Wellness   General Wellness Segment contribution to total sales 17.46 % of total Revenue
Outside The United States   Outside The United States Segment contribution to total sales 5.95 % of total Revenue
In License Or Other   In License Or Other Segment contribution to total sales 0.3 % of total Revenue
Product UNITED STATES   Product UNITED STATES Segment contribution to total sales 94.61 % of total Revenue
Product UNITED KINGDOM   Product UNITED KINGDOM Segment contribution to total sales 5.33 % of total Revenue
Product Other Countries   Product Other Countries Segment contribution to total sales 0.62 % of total Revenue
License JAPAN   License JAPAN Segment contribution to total sales 0.2 % of total Revenue
Bioelectronic Innovations Segment   Bioelectronic Innovations Segment Segment contribution to total sales 100.77 % of total Revenue
TACS TIM   TACS TIM Segment contribution to total sales 1.33 % of total Revenue


Twelve months ended 2025
ECOR s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
United States Rx 24.07 75.73 %
General Wellness 5.55 17.46 %
Outside The United States 1.89 5.95 %
In License Or Other 0.10 0.3 %
Product UNITED STATES 30.08 94.61 %
Product UNITED KINGDOM 1.70 5.33 %
Product Other Countries 0.20 0.62 %
License JAPAN 0.07 0.2 %
Bioelectronic Innovations Segment 32.03 100.77 %
Total 31.79 100 %
TACS TIM 0.42 1.33 %


Twelve months ended 2025
ECOR s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Bioelectronic Innovations Segment 27.79 86.75 %
Total -13.97 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
United States Rx 24.69 % -
General Wellness 97.4 % -
In License Or Other 17.07 % -
Product UNITED STATES 28.9 % -
Product UNITED KINGDOM 1.74 % -
Product Other Countries 65.55 % -
License JAPAN 0 % -
Bioelectronic Innovations Segment 27.2 % 29.87 %
Total 30.29 % -
Rx gammaCore - U S Commercial - -
Outside the United States - -
Truvaga - -
TAC-STIM - -
TACS TIM -64.75 % -
Rx gammaCore - VA - -
United States - -
United Kingdom - -
Other - -
Japan - -
Medical Devices - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.